Analysis Of Efficacy Of Rifaximin In The Treatment Of Digestive Diseases

Objective: To evaluate the effectiveness and safety of rifaximin and quinolones （ciprofloxacinand levofloxacin） in the treatment of infectious diarrhea.Methods: Data were retrieved form PUBMED, EM BASE, Web of Science, The CochraneCentral Register of Controlled Trials, Chinese Journals Full-text Database,Chinese Biomedical Database and Wan Fang Digital Journal Full-text database tocollect clinical randomized controlled trials regarding the treatment of infectiousdiarrhea by rifaximin and ciprofloxacin or levofloxacin. Statistical analysis wasperformed by Meta-analysis using Review Manager5.2.3.Results: Twelve randomized controlled trials including2315cases met the inclusion criteria.M eta-analysis showed that: The clinical effectiveness of Rifaximin was equivalent tocontrol group（RR：1.00，95%CI：0.98-1.03，P=0.85）. Adverse events in the patientstreated with rifaximin were similar to quinolones（RR：1.03，95%CI：0.80-1.31，P=0.84）.Conclusion: Rifaximin can be used for infectious diarrhea patients as effective as quinoloneswith a similar safety profile. Objective: To evaluate the effect of rifaximin and other oral agents in the of patients with hepatic encephalopathy(HE).Methods: Data were retrieved form PUBMED, EM BASE, Web of Science, The CochraneCentral Register of Controlled Trials, Chinese Journals Full-text Database, ChineseBiomedical Database and Wan Fang Digital Journal Full-text database to collectclinical randomized controlled trials regarding the treatment of HE by rifaximin andNon-absorbable disaccharides or other oral antibiotics. Statistical analysis wasperformed by Meta-analysis using Review Manager5.2.3.Results: Thirteen randomized controlled trials including1085HE cases met the inclusioncriteria. M eta-analysis showed that: The clinical effectiveness of Rifaximin wasremarkable compared with placebo（RR：2.24，95%CI：1.20-4.17，P=0.01）,andequivalent to Non-absorbable disaccharides(RR：1.11，95%CI：0.89-1.38，P=0.37）or other oral antibiotics（RR：1.03，95%CI：0.89-1.19，P=0.71）.But the analysis ofsubgroup showed that the changes of electroencephalographic response and grades ofportosystemic encephalopathy were superior in patients treated with rifaximin incomparison to Non-absorbable disaccharides(WMD=-0.21，95%CI:-0.34--0.09，P=0.0007,and WMD=-2.38，95%CI:-2.64--2.11，P<0.00001,respectively）. Patientstreated with rifaximin showed less adverse events（RR：0.13，95%CI：0.07-0.22，P<0.00001）in comparison to Non-absorbable disaccharides.Conclusion: Rifaximin can be used for HE patients as effective as other agents with a bettersafety profile. Objective: To evaluate the effectiveness and safety of rifaximin and placebo in the treatment of Irritable Bowel Syndrome.Methods: Data were retrieved form PUBMED, EM BASE, Web of Science, The CochraneCentral Register of Controlled Trials, Chinese Journals Full-text Database,Chinese Biomedical Database and Wan Fang Digital Journal Full-text database tocollect clinical randomized controlled trials regarding the treatment of IrritableBowel Syndrome by rifaximin or placebo. Statistical analysis was performed byMeta-analysis using Review Manager5.2.3.Results: Four randomized controlled trials including1733cases met the inclusion criteria.M eta-analysis showed that: Rifaximin was more efficacious than placebo for globalIrritable Bowel Syndrome symptom improvement（RR：1.29，95%CI：1.14-1.45，P<0.0001）， Rifaximin was significantly more likely to improve bloating than placebo（RR：1.32，95%CI：1.16-1.49，P<0.0001）.Adverse events in the patients treatedwith rifaximin were similar to placebo.Conclusion: Rifaximin can be used for Irritable Bowel Syndrome patients as a new choicewith a effective and safety profile.